Clinical Trials Logo

Seroprevalence clinical trials

View clinical trials related to Seroprevalence.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04839913 Completed - Covid19 Clinical Trials

Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study

COVID-19
Start date: September 1, 2020
Phase:
Study type: Observational

The investigator analyzed the data of the patients admitted to the surgical department during the period 1St September - 10Th December 2020 to estimate the seroprevalence of SARS-CoV-2 infection in the setting of a non-dedicated COVID-19 hospital and in a mild CoV-2 incidence area and to evaluate the difference of seroprevalence between Spring and Fall seasons in a cohort of patients undergoing surgery.

NCT ID: NCT04699058 Completed - SARS-CoV Infection Clinical Trials

COVID-19 Sero-prevalence Health Care Workers Kinshasa

PRESTACOV
Start date: July 17, 2020
Phase:
Study type: Observational

This is a cohort study, in which the investigators will follow-up 650 health care workers (HCW) and a selection of their households (of COVID positive and COVID negative HCW) at baseline and in three follow-up surveys, with 4 to 6 weeks of time interval. The investigators will select HCW from different wards and different health care structures in 5 communes of Kinshasa. Additionally, in the first survey among HCW, the investigators will test with different diagnostic platform to evaluate the performance of serological tests in the African setting and the effect of malaria infection on the performance of tests. An amendment is added to the protocol, stating an additional 2 surveys in april/June 2021 and October/November 2021 to evaluate impact of second wave and of vaccination campaign.

NCT ID: NCT01861613 Completed - Hepatitis B Clinical Trials

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

Start date: September 2009
Phase: Phase 4
Study type: Interventional

At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.